Tango Therapeutics TNGX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $5.63M-28.6% | $7.89M+19.2% | $6.62M+355% | $1.46M+194% | ||
| $62.38M+48.3% | $42.07M+15.2% | $36.53M+46.9% | $24.86M-32.9% | ||
| $132.17M-8.2% | $143.92M+24.9% | $115.2M+8.8% | $105.91M+36.4% | ||
| $173.67M-7.5% | $187.67M+24.5% | $150.7M+10.9% | $135.93M+42.7% | ||
| $173.67M-7.5% | $187.67M+24.5% | $150.7M+10.9% | $135.93M+42.7% | ||
| $9.7M-37.4% | $15.5M+23.4% | $12.56M+326% | $2.95M+1,094% | ||
| -$101.59M+22.0% | -$130.3M-28.1% | -$101.74M+5.9% | -$108.18M-85.8% | ||
| -162.9%+147pp | -309.7%-31.2pp | -278.5%+157pp | -435.1%-278pp | ||
| -$0.87+27.5% | -$1.20-11.1% | -$1.08+12.2% | -$1.23-30.9% | ||
| 448M+3.2% | 434.2M+17.9% | 368.2M+4.8% | 351.2M— | ||
| -$101.71M+21.9% | -$130.15M-33.0% | -$97.85M+11.9% | -$111.12M-88.3% | ||
| $5.63M-28.6% | $7.89M+19.2% | $6.62M+355% | $1.46M+194% | ||
| $222.5M+367% | $47.66M-42.2% | $82.41M+5,003% | $1.62M— | ||
| -$40.87M-147% | $86.13M— | —— | —— | ||
| -$138.89M-5.6% | -$131.5M-11.5% | -$117.98M-8.2% | -$109.08M-179% | ||
| $4.07M-46.5% | $7.61M+28.1% | $5.94M+298% | $1.49M+702% | ||
| $36K— | —— | —— | $8K— | ||
| -$109.01M+23.8% | -$143.1M-28.0% | -$111.76M-2.1% | -$109.46M-162% | ||
| -174.7%+165pp | -340.1%-34.2pp | -306%+134pp | -440.3%-328pp | ||
| -$111.29M+23.6% | -$145.6M-27.5% | -$114.17M-2.8% | -$111.07M-161% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Tango Therapeutics's income statement data come from?
- Every line is extracted from Tango Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.